logo
logo

Solu Therapeutics Appoints Enda Moran As Chief Operating Officer

Jun 16, 2025•about 2 months ago

Position

Chief Operating Officer

Company

Solu Therapeutics

Enda Moran
BostonTherapeuticsBiotechnologyHealth Care

Description

Solu Therapeutics announced the appointment of Enda Moran, PhD, MBA as Chief Operating Officer (COO). His extensive experience in biomanufacturing and operations will be crucial as the company progresses with its clinical trials and develops transformative therapies.

Company Information

Company

Solu Therapeutics

Location

Boston, Massachusetts, United States

About

Solu Therapeutics, a precision-medicine company, is developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates, licensed from GSK, unlocks antibody-intractable cell surface targets providing the capability to develop next generation medicines that harness the power of biologics with the vast target binding space of small molecules. Unique characteristics of CyTaC platform molecules include: (i) unlocking new tumor-associated antigens to eliminate cancer cells, (ii) depleting pathogenic immune cells, and (iii) extending the half-life of small molecule antagonists and agonists.

Related People

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months